| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERI.12.81 |
| P698 | PubMed publication ID | 23030322 |
| P50 | author | Esteban C Nannini | Q39392197 |
| G Ralph Corey | Q115862748 | ||
| Martin E Stryjewski | Q115862786 | ||
| P2860 | cites work | Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus | Q24556635 |
| Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation | Q39686295 | ||
| Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices | Q39771366 | ||
| In vitro activity of TD-6424 against Staphylococcus aureus | Q40130630 | ||
| Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q40216245 | ||
| Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies | Q41807543 | ||
| Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. | Q42049579 | ||
| Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model | Q42627265 | ||
| Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia | Q42905478 | ||
| Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia | Q43170102 | ||
| Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects | Q43184655 | ||
| Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria | Q43553034 | ||
| Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | Q43781411 | ||
| Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System | Q44727502 | ||
| Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria | Q44803993 | ||
| Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects | Q44938149 | ||
| Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). | Q45013095 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin | Q46489824 | ||
| Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia | Q46589068 | ||
| Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms | Q46620675 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. | Q53544946 | ||
| Ventilator-associated pneumonia | Q28212947 | ||
| A measurement of the efficacy of nosocomial infection control using the 95 per cent confidence interval for infection rates | Q30463029 | ||
| Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis | Q33390834 | ||
| Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects | Q33554391 | ||
| In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates | Q33876626 | ||
| Nosocomial MRSA pneumonia: data from recent clinical trials | Q33935295 | ||
| Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus | Q34077052 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary | Q34158152 | ||
| The impact of hospital-acquired bloodstream infections | Q34213597 | ||
| Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model | Q34309620 | ||
| Tissue penetration of telavancin after intravenous administration in healthy subjects | Q34352132 | ||
| Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study | Q34509652 | ||
| Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens | Q34699108 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Penetration of vancomycin into epithelial lining fluid in healthy volunteers | Q35598408 | ||
| Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients | Q35808723 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| Glycopeptides in clinical development: pharmacological profile and clinical perspectives. | Q35879826 | ||
| Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. | Q36282000 | ||
| Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics | Q36422696 | ||
| Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 | ||
| Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria | Q36670352 | ||
| Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia | Q37769547 | ||
| P433 | issue | 8 | |
| P921 | main subject | pneumonia | Q12192 |
| hospital-acquired pneumonia | Q1957663 | ||
| telavancin | Q7695658 | ||
| P304 | page(s) | 847-854 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies | |
| P478 | volume | 10 |
| Q57153846 | Antimicrobial Therapy in Community-Acquired Pneumonia in Children |
| Q35669688 | Reversing resistance: The next generation antibacterials |
| Q28078557 | Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer? |
| Q38170557 | Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance |
| Q27015976 | Treatment of Gram-positive infections in critically ill patients |
Search more.